Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1996 Jul;51(7):711–716. doi: 10.1136/thx.51.7.711

Mortality rates from cryptogenic fibrosing alveolitis in seven countries.

R Hubbard 1, I Johnston 1, D B Coultas 1, J Britton 1
PMCID: PMC472494  PMID: 8882078

Abstract

BACKGROUND: Registered mortality from cryptogenic fibrosing alveolitis (CFA) in England and Wales has increased substantially since the specific International Classification of Diseases code for CFA was introduced in 1979. However, since a significant proportion of deaths from CFA are misclassified as post inflammatory fibrosis (PIF), it is possible that the observed rise in CFA mortality is due to diagnostic transfer from this code. To investigate this, and to assess mortality trends in other countries, annual CFA and PIF mortality data from England and Wales, USA, Australia, Scotland, Canada, New Zealand, and Germany were analysed. METHODS: Crude annual mortality rates were calculated and rates standardised by Poisson regression to allow assessment of changes over time and comparison between countries, sexes, and age groups. The relative trends in mortality from CFA and PIF were assessed by calculating the annual ratio of CFA to PIF deaths. RESULTS: Men were more likely than women to die from both CFA and PIF in all countries. The highest standardised CFA mortality rate occurred in England and Wales, and the lowest in Germany. Since 1979 mortality from CFA has increased in England and Wales, Australia, Scotland and Canada, but there was no trend in CFA mortality in New Zealand or Germany. In the USA mortality from CFA was low and has fallen. Mortality from PIF increased in all countries except New Zealand and Germany, and the highest PIF mortality, together with the greatest increase over time, was seen in the USA. Changes over time in the annual ratio of CFA to PIF deaths in all countries were small, implying that diagnostic transfer is not a major cause of the increasing CFA mortality. CONCLUSIONS: Mortality from CFA continues to increase in England and Wales and in many other countries. Diagnostic transfer from PIF does not appear to be a major cause of this.

Full text

PDF
711

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agustí C., Xaubet A., Agustí A. G., Roca J., Ramirez J., Rodriguez-Roisin R. Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow-up. Eur Respir J. 1994 Apr;7(4):643–650. doi: 10.1183/09031936.94.07040643. [DOI] [PubMed] [Google Scholar]
  2. Carrington C. B., Gaensler E. A., Coutu R. E., FitzGerald M. X., Gupta R. G. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med. 1978 Apr 13;298(15):801–809. doi: 10.1056/NEJM197804132981501. [DOI] [PubMed] [Google Scholar]
  3. Coultas D. B., Zumwalt R. E., Black W. C., Sobonya R. E. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994 Oct;150(4):967–972. doi: 10.1164/ajrccm.150.4.7921471. [DOI] [PubMed] [Google Scholar]
  4. De Vuyst P., Dumortier P., Rickaert F., Van de Weyer R., Lenclud C., Yernault J. C. Occupational lung fibrosis in an aluminium polisher. Eur J Respir Dis. 1986 Feb;68(2):131–140. [PubMed] [Google Scholar]
  5. Iwai K., Mori T., Yamada N., Yamaguchi M., Hosoda Y. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med. 1994 Sep;150(3):670–675. doi: 10.1164/ajrccm.150.3.8087336. [DOI] [PubMed] [Google Scholar]
  6. Johnson M. A., Kwan S., Snell N. J., Nunn A. J., Darbyshire J. H., Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax. 1989 Apr;44(4):280–288. doi: 10.1136/thx.44.4.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Johnston I., Britton J., Kinnear W., Logan R. Rising mortality from cryptogenic fibrosing alveolitis. BMJ. 1990 Nov 3;301(6759):1017–1021. doi: 10.1136/bmj.301.6759.1017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Nemery B., Nagels J., Verbeken E., Dinsdale D., Demedts M. Rapidly fatal progression of cobalt lung in a diamond polisher. Am Rev Respir Dis. 1990 May;141(5 Pt 1):1373–1378. doi: 10.1164/ajrccm/141.5_Pt_1.1373. [DOI] [PubMed] [Google Scholar]
  9. Ramage J. E., Jr, Roggli V. L., Bell D. Y., Piantadosi C. A. Interstitial lung disease and domestic wood burning. Am Rev Respir Dis. 1988 May;137(5):1229–1232. doi: 10.1164/ajrccm/137.5.1229. [DOI] [PubMed] [Google Scholar]
  10. Scott J., Johnston I., Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ. 1990 Nov 3;301(6759):1015–1017. doi: 10.1136/bmj.301.6759.1015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Turner-Warwick M., Burrows B., Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax. 1980 Mar;35(3):171–180. doi: 10.1136/thx.35.3.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Turner-Warwick M., Burrows B., Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax. 1980 Aug;35(8):593–599. doi: 10.1136/thx.35.8.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Vallyathan V., Bergeron W. N., Robichaux P. A., Craighead J. E. Pulmonary fibrosis in an aluminum arc welder. Chest. 1982 Mar;81(3):372–374. doi: 10.1378/chest.81.3.372. [DOI] [PubMed] [Google Scholar]
  14. Wells A. U., Cullinan P., Hansell D. M., Rubens M. B., Black C. M., Newman-Taylor A. J., Du Bois R. M. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 1994 Jun;149(6):1583–1590. doi: 10.1164/ajrccm.149.6.8004317. [DOI] [PubMed] [Google Scholar]
  15. Wright P. H., Heard B. E., Steel S. J., Turner-Warwick M. Cryptogenic fibrosing alveolitis: assessment by graded trephine lung biopsy histology compared with clinical, radiographic, and physiological features. Br J Dis Chest. 1981 Jan;75(1):61–70. doi: 10.1016/s0007-0971(81)80008-3. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES